Скачать или смотреть How Eli Lilly’s new platform TuneLab codevelops AI models with biotech

Dr. Aliza Apple, VP of Catalyze360 AI/ML at Eli Lilly, joins Ross Katz to unveil TuneLab—a first-of-its-kind federated learning platform accelerating preclinical drug discovery. Learn how Lilly’s billion-dollar models are empowering early-stage biotechs, the science behind federated learning, and what this means for the future of pharmaceutical R&D.

​​*What You'll Learn in This Episode:*
How Eli Lilly's TuneLab democratizes access to proprietary AI models trained on decades of pharmaceutical data
What federated learning means for IP protection and collaborative data sharing in biotech
Which two key use cases are driving TuneLab’s impact today: small molecule ADME and antibody developability
How TuneLab’s early adopters like Firefly Bio and Superluminal are shaping the platform’s evolution
Why generalizability—not just accuracy—is the true power of collaborative AI in drug development

Meet Our Guest
Dr. Aliza Apple is VP of Catalyze360 AI/ML at Eli Lilly and a biotech trailblazer with deep roots in AI-driven drug discovery. She has led initiatives from founding startups to heading Lilly Gateway Labs and now pioneers innovation at the intersection of data and biotech.

About The Host
Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:
Sponsor: CorrDyn, a data consultancy: https://www.corrdyn.com/
Connect with Aliza Apple on LinkedIn:   / aliza-apple  

Connect with Us:
Follow the podcast for more insightful discussions on the latest in biotech and data science.
Subscribe and leave a review if you enjoyed this episode!
Connect with Ross Katz on LinkedIn:   / b-ross-katz  

Sponsored by…
This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.